Last updated on September 2017

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC


Other Details:

For more information, please contact:
844.229.3710
646.776.7532 (local)
Bayer@emergingmed.com

For Study Locations, Click Here



Find a site near you

Start Over

Research Center

Located in: Additional Locations, XX Puerto Rico
1.23miles
  Connect »